Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking and Finance Review - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > Merck to scrap London drug research centre
    Headlines

    Merck to scrap London drug research centre

    Published by Global Banking and Finance Review

    Posted on September 10, 2025

    2 min read

    Last updated: January 22, 2026

    Merck to scrap London drug research centre - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:researchinnovationUK economyinvestment

    Quick Summary

    Merck is closing its London research center, affecting 125 employees, and relocating operations to the US due to the UK's challenging business environment.

    Merck to scrap London drug research centre

    (Reuters) - Merck said on Wednesday it was scrapping research operations in London, citing the UK's challenging business environment, and would relocate the research activity to existing sites primarily in the United States.

    The U.S. drugmaker no longer plans to occupy the Belgrove House site at King's Cross, which was due to open in 2027. The move will impact about 125 staff members.

    Pharmaceutical companies have been shoring up investments in the U.S. amid the Trump administration's tariff threats and pressure to move more manufacturing to the U.S.

    Merck said its decision "reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments."

    The company intends to also vacate laboratories occupied at the London Bioscience Innovation Centre and the Francis Crick Institute by the end of 2025.

    Merck earlier this year announced a series of major U.S. investments, including a $1-billion facility in Delaware to produce biologics and its blockbuster cancer drug Keytruda, which is expected to create over 4,500 jobs.

    The plant is slated to be operational by 2028, with experimental drug production starting by 2030.

    Merck also opened a $1-billion facility at its North Carolina site in March.

    The company's animal health unit will also invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

    (Reporting by Siddhi Mahatole in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Shailesh Kuber)

    Key Takeaways

    • •Merck is closing its London research center.
    • •The move affects 125 employees.
    • •Operations will relocate primarily to the US.
    • •Merck cites UK's challenging business environment.
    • •Major US investments include a $1B Delaware facility.

    Frequently Asked Questions about Merck to scrap London drug research centre

    1Why is Merck relocating its research operations?

    Merck cited the UK's challenging business environment and a lack of meaningful progress in addressing investment issues in the life science industry as reasons for relocating its research operations.

    2How many staff members will be affected by Merck's decision?

    The decision to scrap the London research operations will impact about 125 staff members.

    3What are Merck's plans for its facilities in London?

    Merck plans to vacate the Belgrove House site at King's Cross and laboratories at the London Bioscience Innovation Centre and the Francis Crick Institute by the end of 2025.

    4What investments has Merck made in the U.S. recently?

    Merck has announced major investments in the U.S., including a $1 billion facility in Delaware and another $1 billion facility in North Carolina, as part of a broader $9 billion investment through 2028.

    5When is the new facility in Delaware expected to be operational?

    The new facility in Delaware is slated to be operational by 2028, with experimental drug production expected to start by 2030.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Ukraine energy minister warns of more power cuts, possible Russian attacks
    Ukraine energy minister warns of more power cuts, possible Russian attacks
    Image for Melania Trump says talks with Putin team continue to free Ukrainian kids
    Melania Trump says talks with Putin team continue to free Ukrainian kids
    Image for Fifty-five thousand Ukrainian soldiers killed on battlefield, Zelenskiy tells French TV
    Fifty-five thousand Ukrainian soldiers killed on battlefield, Zelenskiy tells French TV
    Image for Telegram's Durov says proposed Spanish social media restrictions seek to censor critics
    Telegram's Durov says proposed Spanish social media restrictions seek to censor critics
    Image for French president's top diplomat held talks in Moscow on Tuesday, sources say
    French president's top diplomat held talks in Moscow on Tuesday, sources say
    Image for Italy probes 80-year-old over alleged Sarajevo 'sniper tourism'
    Italy probes 80-year-old over alleged Sarajevo 'sniper tourism'
    Image for Dental sector may steady in 2026, but full recovery remains distant, analysts say
    Dental sector may steady in 2026, but full recovery remains distant, analysts say
    Image for Russia says it's open to diplomacy but will counter any new threats after expiry of nuclear treaty
    Russia says it's open to diplomacy but will counter any new threats after expiry of nuclear treaty
    Image for Exclusive-EU rethinks climate diplomacy after bruising COP30 summit, document shows
    Exclusive-EU rethinks climate diplomacy after bruising COP30 summit, document shows
    Image for UK police ask government to withhold some Mandelson documents
    UK police ask government to withhold some Mandelson documents
    Image for Automakers back Trump plan to roll back fuel economy rules, but seek changes
    Automakers back Trump plan to roll back fuel economy rules, but seek changes
    Image for Hungarian court jails left-wing German activist for 8 years for assault
    Hungarian court jails left-wing German activist for 8 years for assault
    View All Headlines Posts
    Previous Headlines PostBritain's Prince Harry meets father King Charles for first time in 20 months
    Next Headlines PostAnalysis-Suspected Russian incursion in Poland raises drone defence questions for NATO